December 23, 2020
Takeda Pharmaceutical and PeptiDream said on December 22 that they have concluded a collaborative research and exclusive license pact for the development of peptide-drug conjugates (PDCs) for neuromuscular diseases. Under the deal, PeptiDream will receive an undisclosed sum of an...read more